Continuous infusion of porcine factor VIII in patients with haemophilia A and high-responding inhibitors: Stability and clinical experience

Haemophilia

Volumn 7, Issue 6, 2001, Pages 537-543

  O'Gorman, P ^a   Dimichele, D M ^b   Kasper, C K ^c   Mannucci, P M ^d   Santagostini, E ^d   Hay, C R M ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c JOINT REPLACEMENT INSTITUTE   (United States)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Continous inufusion of porcine FVIII

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTIHISTAMINIC AGENT; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 8C; PROTHROMBIN COMPLEX; STEROID; ALLOANTIBODY; BLOOD CLOTTING FACTOR 8;

ADOLESCENT; ADULT; ANAMNESIS; ARTICLE; BLOOD TRANSFUSION REACTION; BOLUS INJECTION; BRONCHOSPASM; CHILD; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSS REACTION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; HEMOPHILIA A; HUMAN; INFANT; INTERMETHOD COMPARISON; MULTICENTER STUDY; PATIENT SELECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUBSTITUTION THERAPY; SWINE; THROMBOCYTE COUNT; THROMBOPHLEBITIS; TREATMENT FAILURE; URTICARIA; ANIMAL; BLEEDING; BLOOD; DRUG SCREENING; IMMUNOLOGY; INFUSION; PRESCHOOL CHILD; STANDARD; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANIMAL; CHILD; CHILD, PRESCHOOL; DRUG EVALUATION; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMAN; INFANT; INFUSIONS, PARENTERAL; ISOANTIBODIES; PLATELET COUNT; RETROSPECTIVE STUDIES; SWINE; TREATMENT OUTCOME; ANIMALS; HUMANS;

EID: 0035543813     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2001.00558.x     Document Type: Article

References (16)

1. Comparison of continuous and intermittent factor VIII concentrate therapy in haemophilia A
2. Continuous infusion of factor VIII for surgery and major bleeding
3. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand Disease
4. Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery
5. Monoclonal purified FVIII for continuous infusion: Stability, microbiological safety and clinical experience
6. Vitro factor VIII recovery during the delivery of ultrapure factor VIII concentrate by continuous infusion
7. Vitro stability of porcine factor VIII (Hyate:C)
8. Recommendations for the treatment of factor VIII inhibitors: From the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party
9. Safety profile of porcine factor VIII and its use as hospital and home therapy for patients with haemophilia A and inhibitors: The results of an international survey
10. Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors
11. Clinical experience with polyelectrolyte-fractionated porcine FVIII concentrate in the treatment of haemophiliacs with antibodies to FVIII
12. Adverse effects of treatment with porcine factor VIII
13. A more uniform measurement of factor VIII inhibitors
14. Continuous infusion of porcine factor VIII in the management of patients with factor VIII inhibitors
15. Continuous infusion of porcine factor VIII for the treatment of patients with factor VIII inhibitors
16. Interaction of porcine von Willebrand factor with the platelet glycoproteins Ib and IIb/IIIa complex